Indivior + Opiant, Regeneron + CytomX, Rezo, Provention
Nov 22 2022
Length: 6 mins
Podcast

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to Cart failed.

Please try again later

Add to Wish List failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Please try again

Unfollow podcast failed

Please try again

Indivior + Opiant, Regeneron + CytomX, Rezo, Provention

Listen for free

View show details

Summary
A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvals

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Indivior + Opiant
Regeneron + CytomX
Rezo
Provention

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Show more Show less

Show more Show less

What listeners say about Indivior + Opiant, Regeneron + CytomX, Rezo, Provention

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

No Reviews are Available